{
    "nctId": "NCT00675259",
    "briefTitle": "Phase II NCT (Neoadjuvant Chemotherapy) w/ Weekly Abraxane in Combination With Carboplatin & Bevacizumab in Breast Cancer",
    "officialTitle": "Phase II Trial of Neoadjuvant Chemotherapy [NCT] With Weekly Nanoparticle Albumin-bound Paclitaxel [Nab-paclitaxel; Abraxane\u00ae] in Combination With Carboplatin and Bevacizumab in Women With Clinical Stages I-III Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 33,
    "primaryOutcomeMeasure": "Number of Patients With Pathologic Complete Response (pCR)",
    "eligibilityCriteria": "Inclusion:\n\n* Histologically confirmed breast cancer\n* Clinically or radiographically measurable residual tumor after core biopsy\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n* Age \u226518 yrs\n* Absolute neutrophil count \u2265 1,500/mm\u00b3\n* Hemoglobin \u2265 9 g/dL\n* Platelet count \u2265 100,000/ mm\u00b3\n* Creatinine \u2264 1.5 times upper limit of normal (ULN)\n* Urine protein:creatinine ratio \\< 1.0\n* AST (aspartate aminotransferase) and ALT \u2264 2.5 times ULN\n* Alkaline phosphatase \u2264 2.5 times ULN\n* Bilirubin normal\n* Women of childbearing potential must use effective contraception\n* Left ventricular ejection fraction (LVEF) normal by echocardiogram or MUGA\n\nExclusion:\n\n* No residual tumor after initial biopsy\n* Peripheral neuropathy of grade 2 or higher\n* HER-2 neu overexpression either by IHC 3+ or FISH+\n* No history of any prior treatment of breast cancer.\n* No history of unstable angina or myocardial infarction within the past 12 months\n* Pregnant or nursing women\n* Anticoagulation therapy within the last 6 months\n* History of gastrointestinal bleeding\n* Recent hemoptysis\n* No known hepatitis B or HIV seropositivity\n* No inadequately controlled hypertension, defined as systolic blood pressure (BP) \\> 150 mm Hg and/or diastolic BP \\> 100 mm Hg despite antihypertensive medications\n* History of hypertensive crisis or hypertensive encephalopathy\n* New York Heart Association class II-IV congestive heart failure\n* History of stroke or transient ischemic attack at any time\n* Significant vascular disease (e.g., aortic aneurysm or aortic dissection)\n* No symptomatic peripheral vascular disease\n* Evidence of bleeding diathesis or coagulopathy\n* Significant traumatic injury within the past 28 days\n* History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months\n* Serious, non-healing wound, ulcer, or bone fracture\n* Known hypersensitivity to any component of bevacizumab",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}